$3.7 Billion Market for Parkinson’s Drugs Could Prove Key to RBCC’s Growth

NOKOMIS, Fla.--(BUSINESS WIRE)--

As demand for effective diagnostics and treatments for Parkinsons Disease grows around the globe, Rainbow BioSciences (OTCBB: RBCC.OB - News) is working to capitalize by helping to deliver promising new therapies to market.

RBCC announced today that the company plans to sign a letter of intent with a drug development company that could be on the verge of promising new diagnostic and therapeutic tools for Parkinsons patients and their doctors.

The increasing market potential for Parkinsons therapies is what attracted RBCCs attention to the developing company. The market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain. Growth in the Parkinson's treatment market is being driven by new breakthroughs, and RBCC could potentially help advance the timeline for a cure for the debilitating disease.

RBCC plans to continue discussing deals with emerging drug therapy companies in an effort to speed that cure along.

For more information on RBCCs biotechnology initiatives, please visit http://www.rainbowbiosciences.com/investors.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC.OB - News). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visitwww.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Follow this link:
$3.7 Billion Market for Parkinson’s Drugs Could Prove Key to RBCC’s Growth